Specialized Hospital For Active Cardiology Treatment Medica Kor EAD
- Address
- Ulitsa Riga 35, 7013 Rousse, Bulgaria
Lipid Management & LDL‑Cholesterol Reduction
The Specialized Hospital For Active Cardiology Treatment Medica Kor EAD conducts research in cardiovascular disease. The trials target hypercholesterolemia and evaluate a novel RNA‑based therapy to improve LDL‑C control.
- Assess proportion of participants achieving individualized LDL‑C targets
- Evaluate safety when added to standard lipid‑lowering regimens
- Measure impact on patient‑reported quality of life
Two investigators oversee the program, highlighting the site’s focus on preventive cardiology.
Hypertrophic Cardiomyopathy Symptom Improvement
The Department of Cardiology at the hospital addresses structural heart disease. This study enrolls patients with hypertrophic cardiomyopathy to test a new SGLT‑1/2 inhibitor for symptom relief.
- Track changes in exercise capacity and functional limitation
- Compare symptom scores between active treatment and placebo
- Monitor safety and tolerability in a high‑risk population
The project involves two senior cardiologists and reflects ongoing efforts to enhance quality of life for HCM patients.
Inflammation Modulation After Heart Attack
Researchers at the site focus on acute coronary events. The trial investigates ziltivekimab as an early intervention for patients experiencing myocardial infarction to lower inflammatory markers and event risk.
- Initiate therapy shortly after STEMI or NSTEMI
- Evaluate reduction in major adverse cardiovascular events
- Observe safety when combined with standard post‑MI care
With two investigators leading, the study underscores the hospital’s commitment to innovative post‑acute care strategies.
Blood Pressure Control in High‑Risk Patients
The clinic’s cardiovascular program also targets persistent hypertension. This research examines zilebesiran in individuals with high cardiovascular risk to determine its effect on blood pressure and event outcomes.
- Determine impact on cardiovascular death, non‑fatal MI, and stroke
- Assess reduction in systolic and diastolic blood pressure
- Compare efficacy against placebo in a high‑risk cohort
The study is driven by two principal investigators, reflecting the site’s dedication to improving hypertension management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Alnylam Pharmaceuticals Inc.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Specialized Hospital For Active Cardiology Treatment Medica Kor EAD
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| ARTEMIS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with acute myocardial infarction. | Novo Nordisk A/S | Phase III | Not Recruiting | Aug 2024 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ab-1002 | 1 | Unknown | 2024-11-05 | 2024-11-05 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.